benefit
(statisticaly significant)
benefit (nominaly significant, not statitically demonstrated) NS not significant harm statitically significant NS harm not significant low certainty due to bias
 
DCR

hepatocell cancer (HCC) hepatocell cancer (HCC)

versus placebo
pembrolizumab based treatment vs. placebo 1 -

mHCC - (neo)adjuvant (NA) metastatic/advanced hepatocellular cancer (mHCC) mHCC - (neo)adjuvant (NA)

mHCC - 1st line (L1) metastatic/advanced hepatocellular cancer (mHCC) mHCC - 1st line (L1)

versus lenvatinib
pembrolizumab plus lenvatinib vs. lenvatinib 1 -

mHCC - 2nd line (L2) metastatic/advanced hepatocellular cancer (mHCC) mHCC - 2nd line (L2)

versus placebo
pembrolizumab alone vs. placebo 1 NS
pembrolizumab based treatment vs. placebo 1 NS